Royalderm Agnieszka Nawrocka

Clinical trial activity at Royalderm Agnieszka Nawrocka in Warsaw focuses on dermatology, with strong emphasis on skin and connective tissue diseases and related immune system diseases. The studies are largely aimed at testing new treatments, comparing them with existing options, and understanding longer-term safety and effectiveness in common and complex skin conditions.

• Atopic dermatitis and related eczema research, including studies of new therapies to improve symptom control, itch relief, and everyday quality of life
• Hidradenitis suppurativa trials exploring better ways to reduce inflammation, pain, and disease activity in this chronic skin condition
• Psoriasis research evaluating whether emerging treatments can offer effective and durable control of plaque disease

Overall, the site is active in studies designed to refine treatment choices for inflammatory skin disorders and to support safer, more effective care for patients who need advanced systemic therapy.

A major part of the research portfolio addresses immune system diseases that affect the skin, with trials centered on reducing immune-driven inflammation and improving disease control. These studies often compare investigational medicines with placebo or established therapies to see whether they can better manage chronic symptoms and visible skin changes.

• Atopic dermatitis studies assessing new options for controlling flare-ups, itching, and skin barrier-related symptoms
• Chronic spontaneous urticaria and chronic inducible urticaria research focused on easing hives and persistent itching
• Vitiligo trials examining treatments intended to support repigmentation and improve long-term skin appearance

This research reflects a strong interest in immune-mediated skin inflammation and in therapies that may offer more personalized disease management for patients seen at the site.

The site also participates in clinical research for conditions that affect hair growth and skin pigmentation, including alopecia areata and vitiligo. These trials are designed to test whether newer treatments can restore hair growth or improve pigmentation while remaining safe over time.

• Alopecia areata studies evaluating treatments for severe or persistent hair loss
• Nonsegmental vitiligo research focused on improving repigmentation and treatment durability
• Long-term follow-up studies aimed at understanding sustained benefit and tolerability

In this area, the research emphasizes both visible improvement and the practical impact of treatment on confidence and daily life, making it an important part of the site’s broader dermatology program.

Another key research theme is hidradenitis suppurativa, a painful and often difficult-to-treat inflammatory skin disease. Trials at the site are evaluating new approaches that may reduce lesions, discomfort, and disease flare frequency, while also examining safety in longer-term use.

• Hidradenitis suppurativa studies testing new therapies for symptom reduction and improved disease control
• Prurigo nodularis research aimed at easing itch and skin lesions
• Chronic cutaneous lupus erythematosus and subacute cutaneous lupus erythematosus studies exploring options for refractory skin disease

These trials highlight the site’s involvement in managing challenging chronic inflammatory conditions where better treatment options are still needed.

Beyond inflammatory diseases, Royalderm Agnieszka Nawrocka contributes to research in skin lesion treatment and other dermatologic conditions, including actinic keratosis, acne vulgaris, and plaque psoriasis. The purpose of these studies is to assess whether new topical or systemic approaches can improve lesion clearance, symptom relief, and overall treatment effectiveness.

• Actinic keratosis trials focused on clearing precancerous skin lesions and monitoring long-term safety
• Acne vulgaris studies evaluating new topical treatments for persistent acne
• Plaque psoriasis research comparing emerging therapies with established care to improve control of skin plaques

Together, these studies show a broad dermatology portfolio that spans chronic inflammation, pigment disorders, hair loss, and skin lesion management.